Welcome to the e-CCO Library!

P430 Feasibility and reliability of gastrointestinal ultrasound in pregnant inflammatory bowel disease patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F. de Voogd1, H. Joshi2, E. Van Wassenaer1, G. D’Haens1, K. Gecse1

Created: Thursday, 30 January 2020, 10:12 AM
P430: Distinct faecal bile acid profiles are associated with sustained remission following exclusive enteral nutrition (EEN) induction therapy in paediatric Crohn's disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Connors1*, R. Bandsma2, B. MacIntyre1, S. Whitehouse1, A. Noble1, M. Rashid1, A. Otley1, J. Van Limbergen1

Created: Thursday, 21 February 2019, 9:14 AM
P430: EirSwitch echoes of NorSwitch: switching biosimilar therapy in an IBD cohort an Irish experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Nugent S.*1, Nugent M.2, Mullane D.1, Kelly C.1

Created: Wednesday, 20 February 2019, 10:36 AM
P430: European clinician perspective on withdrawing immunosuppression
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Boyapati1, S. R. Fehily*2, N. S. Ding3

Created: Friday, 22 February 2019, 9:41 AM
P430: Longer-term tofacitinib effectiveness for the treatment of ulcerative colitis: Two-year outcomes from a UK observational cohort study
Year: 2022
Source: ECCO'22
Authors: Honap, S.(1,2);Sharma, E.(1);Ray, S.(1);Mawdsley, J.(1);Anderson, S.(1);Samaan, M.(1);Pavlidis, P.(1,2);Irving, P.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
P430: Mesalazine dose modification based on fecal calprotectin levels in ulcerative colitis patients in clinical remission
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Piñero, G.S.(1,2,3)*;Mañosa , M.(1,3);Cañete, F.(1,3);Calafat, M.(1,3);González, L.(1,3);Ruffinengo, O.(2);Domènech, E.(1,3);
Created: Friday, 14 July 2023, 11:05 AM
P430: Prognostic significance of neuropeptide expression in ileal neural plexuses in Crohn’s disease. A retrospective study.
Year: 2021
Source: ECCO'21 Virtual
Authors: Gklavas, A.(1);Tiniakos, D.(2);Karandrea, D.(2);Karamanolis, G.(3);Bamias, G.(4);Papaconstantinou, I.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P430: Prognostic significance of serial faecal calprotectin in inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

Y. Zhulina1, Y. Cao2, K. Amcoff3, M. Carlson3, C. Tysk1, J. Halfvarson*1

Created: Friday, 22 February 2019, 9:49 AM
P431 Vitamin D binding protein in the limelight: IBD-related inflammation and circulating levels of vitamin D binding protein, total, free and bioavailable 25-hydroxyvitamin D
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Aksan1,2,3, K. Böttger2,4, N. Hein4, Y. Caicedo-Zea5, I. Diehl6, C. Schumann5, F.P. Armbruster7, J.M. Stein1,2,4

Created: Thursday, 30 January 2020, 10:12 AM
P431: A Pan-European Real-World Study of SB5 biosimilar following transition from reference adalimumab: The PROPER study; 48-week analysis of persistence
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dignass, A.(1)*;Gisbert, J.P.(2);Bossa, F.(3);Kelly, O.(4);Rahman, M.(5);Lobatón, T.(6);Addison, J.(7);
Created: Friday, 14 July 2023, 11:05 AM
P431: Colonic Treg levels are reduced in patients with ulcerative colitis achieving clinical remission, but are not differentially affected by etrolizumab dose
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Fuh F., Tew W., Keir M., Looney C., Maciuca R., McBride J., Ramirez-Montagut T.

Created: Wednesday, 20 February 2019, 10:36 AM
P431: Early mucosal healing at week 10 with ozanimod predicts clinical outcomes at week 52: Post hoc analysis of the phase 3 True North clinical trial
Year: 2022
Source: ECCO'22
Authors: Reinisch, W.(1);Axelrad, J.(2);Ahmad, H.A.(3);Pondel, M.(3);Ather, S.(3);Elegbe, A.(3);Sninsky, C.(4);Longman, R.(5);
Created: Friday, 11 February 2022, 3:52 PM
P431: Golimumab dried blood spot analysis (GOUDA): A prospective trial to validate golimumab concentration analysis using the dried blood spot methodology
Year: 2018
Source: ECCO '18 Vienna
Authors:

I. Detrez1*, E. Dreesen1, G. Van Assche2, S. Vermeire2, M. Ferrante2, A. Gils1

Created: Thursday, 21 February 2019, 9:14 AM
P431: Teduglutide use and nutritional outcomes in short bowel syndrome with intestinal failure: a real-world claims database analysis
Year: 2021
Source: ECCO'21 Virtual
Authors: Micic, D.(1);Jiang, J.(2);Chen, L.(2);Fan, T.(2);Mu, F.(3);Satija, A.(4);Downes, N.(5);Shrestha, S.(5);Wu, E.(3);Swallow, E.(6);Wojtowicz, A.(7);Raphael, B.P.(8);
Created: Wednesday, 2 June 2021, 4:12 PM
P431: Transabdominal ultrasonography to assess intestinal wall thickness and vascularity appears to predict therapeutic effects of steroid treatment in moderate-to-severe ulcerative colitis patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Ogashiwa*1, M. Murakami1, S. Tsuda1, M. Nishio1, Y. Kogure1, K. Kasahara1, K. Hirai2, Y. Fukuno2, M. Jin2, A. Hanzawa2, H. Yonezawa2, K. Numata3, H. Kimura1, R. Kunisaki1

Created: Friday, 22 February 2019, 9:49 AM
P431: Validation of a therapeutic drug monitoring test to measure the adalimumab biosimilar SB5 in comparison with the reference adalimumab
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. B. Ruiz-Argüello*1, A. Maguregui1, A. Martínez1, D. Nagore1

Created: Friday, 22 February 2019, 9:41 AM
P432 Effects and safety of a colon-long absorbing budesonide product in patients with mild to moderate ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D. Pigniczki, K. Szántó, M. Rutka, K. Farkas, A. Bálint, R. Bor, A. Fábián, Z. Szepes, T. Molnár

Created: Thursday, 30 January 2020, 10:12 AM
P432: Barriers to prescribing anti-TNF therapy in inflammatory bowel disease (IBD) across newly industrialised emerging market countries: an analysis of the ‘EXPLORE’ study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. D. Ye*1, J. K. Yamamoto Furusho2, M. Rana Qasim Khan3, O. Fadeeva3, D. Demuth4, J. Qian5, I. L. Khalif6, T. Chia-Hung7, M. Toruner8, A. H. Othman9, W. Chan10, E. Ponce de Leon11, M. Guennec12, C. Sison13, E. Uberti Foppa14, A. Armuzzi15

Created: Friday, 22 February 2019, 9:41 AM
P432: Does medical acceleration improve long-term outcomes in ulcerative colitis patients who are in clinical remission but have endoscopic mucosal inflammation?
Year: 2018
Source: ECCO '18 Vienna
Authors:

J.Y. Chang*, J.H. Cheon, Y. Park, S.J. Park, T.-I. Kim, W.-H. Kim

Created: Thursday, 21 February 2019, 9:14 AM
P432: MyChart application in addressing Inflammatory Bowel Disease patients’ concerns and impact on service utilisation
Year: 2021
Source: ECCO'21 Virtual
Authors: P Raman, K.(1);Agorogianni, A.(1);Hadjinicolaou, A.(1);Nightingale, A.(1);Mayhew, A.(1);Munro, R.(1);Raine, T.(1);McDermott, E.(1);
Created: Wednesday, 2 June 2021, 4:12 PM